Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: semantics
Pappythorn: "I don't feel one cent of a dividend is needed to move the PPS to .50" There's a very easy formula as a very rough estimate: A $100M license nets around $40M to PTSC and that's pretty much 10c a share. Sure, taxes and BoD and Cliff payments eat into it a bit but not so much as to make it worth trying to fine tune the calculation. The PTSC business model as it stands has no real room for speculation or organic growth potential it's pretty much "some money in if Leckrone has a good day, spend some on PTSC (bonus, pay increases, party, maybe taxes etc), add some more to the future legal defense fund, set aside some for the PDS party" and then dribble just enough out to placate the shareholders.". Repeat. Maybe we'll see 5c a share per $100M gross license fee, and maybe 3c-4c increase in share price, less trending to 0 as we approach the end of life of MMP litigation.
Share
New Message
Please login to post a reply